Viridian Therapeutics Inc. (VRDN)
VRDN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VRDN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001590750 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $70.8M |
| Net income | -$342.6M |
| Operating income | -$363.4M |
| Net margin | -483.6% |
| Operating margin | -512.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | $899.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 29.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-08 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 815 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -15.8% |
| 3 months | +1.9% |
| Year to date | -41.0% |
| 1 year | -14.0% |
| From 52-week high | -45.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $17.58 | -8.20% | $2.1B |
| PHVS | Pharvaris N.V. | $30.02 | -2.82% | $2.1B |
| PRGO | Perrigo Company plc | $15.37 | -0.52% | $2.1B |
| HRMY | Harmony Biosciences Holdings Inc. | $37.03 | -3.14% | $2.2B |
| IRON | Disc Medicine Inc. | $56.60 | -6.42% | $2.2B |
| AUPH | Aurinia Pharmaceuticals Inc | $16.36 | -1.15% | $2.2B |
| SDGR | Schrodinger Inc. | $25.89 | -0.08% | $1.9B |
| BHC | Bausch Health Companies Inc. | $5.89 | -0.68% | $2.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier